AMRS - Amyris down 8% in after-hours trading on Q4 2022 revenue miss

2023-03-15 18:27:00 ET

• Amyris stock is down ~8% in after-hours trading after the synthetic biotech company reported Q4 2022 financial results that missed on the bottom line.
• Though Q4 2022 revenue of $75.8M was a 17% year-over-year increase, it came in $28.3M below expectations.
• For its 2023 financial outlook, Amyris ( NASDAQ: AMRS ) said it is expecting revenue to grow 95%-100% compared to 2022. In 2022, revenue was ~$269.8M. The 2023 consensus revenue estimate is $505.61M.
• Amyris ( AMRS ) ended 2022 with $64.4M in cash and cash equivalents compared to $483.5M at the end of 2021.
• Read why Seeking Alpha contributor UFD Capital rates Amyris ( AMRS ) a strong sell.

For further details see: